A5074533323- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes and associated disorders
- Sodium Intake and Health
- Pancreatic function and diabetes
- Blood Pressure and Hypertension Studies
- Diabetes Management and Education
- Heart Rate Variability and Autonomic Control
- Nutritional Studies and Diet
- Fault Detection and Control Systems
- Quality and Safety in Healthcare
- Cardiovascular Disease and Adiposity
- Diet and metabolism studies
- Apelin-related biomedical research
- Consumer Attitudes and Food Labeling
- Chronic Disease Management Strategies
- Renal function and acid-base balance
- Cardiovascular Health and Disease Prevention
- Metabolism and Genetic Disorders
- Intravenous Infusion Technology and Safety
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Mobile Health and mHealth Applications
The University of Melbourne
2018-2025
St Vincent's Hospital
2022-2025
RMIT University
2023-2024
Saint Vincent's Catholic Medical Center
2024
Northridge Hospital Medical Center
2023
Austin Health
2016-2019
To determine feasibility and compare acceptance of an investigational Medtronic enhanced advanced hybrid closed-loop (e-AHCL) system in adults with type 1 diabetes earlier iterations.
Introduction Sodium-glucose co-transporter inhibitors have potential glycaemic and non-glycaemic benefits in people with type 1 diabetes (T1D). However, the increased risk of diabetic ketoacidosis (DKA) limits their widespread use. We hypothesise that dapagliflozin 10 mg daily, combined use continuous ketone monitoring (CKM) education strategies to mitigate progression DKA, will demonstrate improved control without increasing DKA events. Methods analysis PARTNER is a multisite 6-month...
AimsUnderstanding the lived experience of using a tubeless insulin pump and how this differs compared to usual care (tubed therapy (IPT) vs multiple daily injections (MDI)).MethodsInterviews were conducted after 12-weeks Omnipod DASH Insulin Management System (Insulet, Acton, MA) analysed thematic analysis.ResultsFifty-eight adults (35 female; mean age 42;SD 13 years; 35 previous MDI) interviewed. Most (84 %) wanted continue device. Experiences fit two themes: 1. Taking back control my...
Objective: Low sodium intake may trigger sympathetic nervous system (SNS) activation and endothelial dysfunction. Studies have not explored these associations along the glucose continuum. Accordingly, we compared function SNS activity in individuals with low differing categories of metabolic risk We hypothesized that is associated (1) impairment (2) higher risk. Research Design Methods: In this prospective observational study, participants (n=54) (single 24 hours urine excretion <150...
Abstract Context Lower sodium intake is paradoxically associated with higher mortality in type 2 diabetes (T2D). Objective To determine whether sympathetic nervous system (SNS) activation and endothelial dysfunction contribute to these observations, we examined the effect of salt supplementation on systems people T2D habitual low sodium. We hypothesized that would lower SNS activity improve function compared placebo. Design conducted a randomized, double-blinded, placebo-controlled crossover...
Devices have facilitated improvement in glycemia individuals with type 1 diabetes mellitus (T1DM), but self-management remains key. It is unclear whether people review their device data before clinic appointment. We assessed this by a survey. T1DM adults using glucose sensors and/or insulin pumps attending an Australian public hospital (diabetes clinics >4 months) were prospectively surveyed. The percentage who uploaded and reviewed was determined interest education facilitating...
Background: Conventional insulin pumps can be inconvenient and increase diabetes distress in people with type 1 (T1D). A tubeless pump discreetly controlled by a handheld device, may more acceptable. This is the first randomized trial on patient-reported outcomes pumps. Aim: To compare treatment satisfaction Omnipod DASH® Insulin Management System (Insulet, Acton MA) vs. usual care (MDI or conventional IPT) T1D adults self-monitoring fingerstick blood glucose. Methods: were to 12-weeks of...
Abstract Background Insulin pump therapy (IPT) improves glucose control in people with type 1 diabetes (T1D) compared multiple daily injections (MDI). However, their size, the tethered insulin infusion set, intrusiveness when operating device and need to disconnect during showering limit acceptance many who may benefit. The Omnipod DASH ® Management System is a small waterproof tubeless which wirelessly controlled by handheld be an acceptable alternative. there are no randomised trials...
Abstract Context Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed therapy (IPT). Objective We compared treatment satisfaction with to usual care (multiple daily injections [MDIs] or IPT) in adults type 1 diabetes using self-monitoring blood glucose (SMBG). Methods Adults on MDI (n = 40) IPT 25) from 4 centers Australia were randomly assigned 1:1 nonblinded manner (Omnipod group) continue (Usual Care for 12...
Aim: To compare device tolerance & participant’s subjective experience wearing a surgically implanted long term glucose sensor versus conventional CGM in adults with Type 1 Diabetes. Method: A prototype (Eclipse 3 sensor, GlySens, San Diego, CA) masked data transmitted to study iPhone was inserted superficial the rectus sheath 8 Adults Diabetes (4 Female; Mean [SD] Age 56 [7]Y; BMI 25[3]). One daily fingerstick calibration required. Participants simultaneously wore TGA approved multi-Day...
Aim: To generate pilot data regarding acceptance, safety, and function of a novel long-term CGM. Methods: The investigational CGM (Eclipse 3, GlySens, San Diego, CA) was surgically inserted superficial to the rectus sheath in 8 type 1 diabetes adults (4 Female; Mean [SD] age 56 [7]; BMI 25 [3]). were masked participants processed retrospectively simulated real-time with one capillary blood glucose calibration per day. Monthly visits evaluated: user acceptance by standardised questionnaire;...
Background: Hybrid closed loop (HCL) systems are evolving. We aimed to assess treatment satisfaction and glucose control with an investigational eAHCL system. Methods: Adults type 1 diabetes (T1D) received sequentially the MiniMed™ 780G /Guardian™ Sensor 3 AHCL system, a Medtronic system each for 12 weeks. The incorporates updated software, new simple use, no calibration, all-in-one sensor, 7 day extended wear infusion set. primary outcome was difference in measured using “current” “change”...
Background: SynerGTM (Pacific Diabetes Technology, Portland, OR), a prototype subcutaneous cannula combining glucose sensing and insulin infusion could reduce the burden on people with diabetes (PWD) using pump therapy (IPT) sensors. Aim: To assess refine sensor accuracy, evaluate site function, user tolerability. Method: Adults type 1 established IPT participated. Following 48-hour run-in commercially available set study (Medtronic 780G), was inserted subcutaneously in anterior abdomen...
<p dir="ltr">Objective: To determine feasibility and compare acceptance of an investigational Medtronic enhanced-Advanced Hybrid Closed Loop (e-AHCL) system in type 1 diabetes adults with earlier iterations.</p><p dir="ltr">Research Design Methods: Non-randomised three-stage (each twelve weeks) exploratory study comparing e-AHCL (Bluetooth®-enabled MiniMed™ 780G insulin pump automatic data upload [780G] incorporating updated algorithm; calibration-free all-in-one disposable...
<p dir="ltr">Objective: To determine feasibility and compare acceptance of an investigational Medtronic enhanced-Advanced Hybrid Closed Loop (e-AHCL) system in type 1 diabetes adults with earlier iterations.</p><p dir="ltr">Research Design Methods: Non-randomised three-stage (each twelve weeks) exploratory study comparing e-AHCL (Bluetooth®-enabled MiniMed™ 780G insulin pump automatic data upload [780G] incorporating updated algorithm; calibration-free all-in-one disposable...
Combining a continuous glucose monitor with an insulin delivery cannula (CGM-IS) could benefit clinical outcomes. We evaluated the feasibility of single-needle insertion electrochemical investigational CGM-IS (Pacific Diabetes Technologies, Portland, Oregon) in type 1 diabetes adults.
Low sodium intake is paradoxically associated with adverse cardiovascular outcomes in individuals type 2 diabetes mellitus (T2D), possibly from renin-angiotensin-aldosterone system (RAAS) activation, leading to endothelial dysfunction. In the present study, we investigated associations between habitual and RAAS blockade on function by measuring circulating microparticles (MPs) T2D.We conducted a prospective, cross-sectional study 74 T2D. Habitual dietary was estimated using mean of three...
Abstract Background Insulin pump therapy (IPT) improves glucose control in people with Type 1 diabetes (T1D) compared multiple daily injections (MDI). However, their size, the tethered insulin infusion set, intrusiveness when operating device, and need to disconnect during showering limits acceptance many who may benefit. The Omnipod DASH® Management System is a small waterproof tubeless device worn on upper arm which wirelessly controlled by handheld be an acceptable alternative. there are...
Background: Tubeless insulin pump therapy (IPT) offers an alternative to tubed pumps and multi-dose injections (MDI) for people with type 1 diabetes (T1D). No formal interview studies have explored individual's lived experiences of using tubeless IPT. Aim: To gain insight into the experience a IPT system compared usual or MDI care. Methods: Interviews were conducted 12-weeks after Omnipod DASH® Insulin Management System (Insulet, Acton MA) in randomised controlled trial. The transcripts...